Holen Sie sich die Stockscreener-App
12.76
0.08%
0.015
Schlusskurs vom Vortag:
$12.74
Offen:
$12.72
24-Stunden-Volumen:
31,922
Relative Volume:
0.16
Marktkapitalisierung:
$173.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-104.29M
KGV:
-2.1142
EPS:
-6.0329
Netto-Cashflow:
$-81.45M
1W Leistung:
-10.46%
1M Leistung:
-10.84%
6M Leistung:
+2.00%
1J Leistung:
+48.72%
1-Tages-Spanne:
$12.65
$12.99
1-Wochen-Bereich:
$11.56
$14.92
52-Wochen-Spanne:
$5.062
$17.43
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
12.75 | 173.83M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-15 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Immunic lines up three July investor events in Boston and SF - stocktitan.net
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Small cap wrap: Immunic, Midnight Sun Mining, Purepoint Uranium... - proactiveinvestors.com.au
Immunic to host virtual R&D day on relapsing MS ahead of Phase 3 trial results - Pluang
Immunic to host virtual relapsing MS R&D Day on September 9 - Yahoo Finance
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
EQS-News: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026boerse.de - boerse.de
Immunic names Chitrang Davé chief data and digital officer - The Pharma Letter
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - Investing News Network
Immunic appoints Chitrang Davé as chief data and digital officer - Yahoo Finance
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Long term debt to total assets ratio of Immunic, Inc. – HAM:10V - TradingView
Discontinued operations of Immunic, Inc. – HAM:10V - TradingView
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Australia
IMUX Initiates Coverage On Wedbush -- Rating Set to Outperform - GuruFocus
Wedbush initiates Immunic stock with Outperform rating - Investing.com
Wedbush Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $45 - Moomoo
Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Immunic Inc. (IMUX) Pulls Back 3.14% to $16.06 as Key Support at $15.26 Comes into FocusCall Flow Alert - Vinanet
Immunic, Inc. (IMUX): OrbiMed entities disclose 5.3% and 2.8% equity holdings - Stock Titan
Nantahala Capital discloses 7.47% Immunic (IMUX) stake in Schedule 13G/A - Stock Titan
Immunic (IMUX): Commodore Capital discloses 9.9% stake capped by warrant limits - Stock Titan
Immunic Inc (NASDAQ: IMUX) Share Price, IMUX Stock News, IMUX Share Price & Updates - Kalkine
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Immunic (IMUX) sees Soleus Capital group disclose 4.9% beneficial stake - Stock Titan
H.C. Wainwright Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Wolfe Research Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Is Immunic Inc (IMUX) Struggling After Recent Earnings? EPS Misses Estimates with GF Score: 32/100 - GuruFocus
LifeSci Capital Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Small cap wrap: 1911 Gold, Dune Oil, Nextech3D.ai, C3 Metals, Immunic… - Proactive financial news
Immunic Releases Q2 2026 Financial Results - AlphaStreet
Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Immunic Inc For: 11 August By Investing.com - Investing.com Nigeria
Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS - MarketBeat
Immunic Appoints Biopharma Finance Veteran Elena Ridloff to Board of Directors - Minichart
Immunic Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Immunic advances MS drug vidofludimus calcium t... - Pluang
Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program - Bitget
Immunic CEO on Q2 progress and Phase 3 MS trial milestones - Proactive financial news
Immunic advances MS drug trials, expects Phase 3 data by end 2026 and plans NDA filing in 2027 - Pluang
Immunic Inc (IMUX) Q2 Earnings Beat Highlights Growth Potential Despite Unprofitability - GuruFocus
Immunic appoints Elena Ridloff to board ahead of Phase 3 MS readout - Quiver Quantitative
Immunic (IMUX) Advances Clinical Stage, Market Eyes Growth Despi - GuruFocus
Immunic: Q2 Earnings Snapshot - AOL.com
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Immunic advances MS drug toward key Phase 3 data, expects results by year-end - Proactive financial news
Immunic files Form 3 for director Elena Ridloff, reporting no beneficial ownership - Bitget
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):